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Atrial fibrillation (AF) is the most common
cardiac arrhythmia in daily medical practice, and is
very often evaluated and treated by non-specialists.
In view of varying clinical presentations and asso-
ciated problems, therapeutic options may vary
widely from one patient to another. For the in-
ternist (and even for the experienced arrhythmia
specialist), straightforward answers are not always
found in the abundant medical literature. System-
atic reviews allow methodological evaluation of
the evidence and the development of guidelines
designed to simplify and harmonise clinical man-
agement [1, 2]. Since 1996 we have conducted an
evaluation of this kind and drawn up simple prac-
tice guidelines to be used in a general internal med-
icine ward. We propose algorithms and tables with
graded recommendations easily usable by inter-
nists and general physicians for the individual care
of atrial fibrillation patients. These guidelines are
not intended to compete with the recently pub-
lished and more extensive international guidelines,
which represent the gold standard for AF manage-
ment, but should rather be considered a simplified
local approach [3]. 
Purpose: Since the management of atrial fibril-
lation may be difficult in the individual patient, our
purpose was to develop simple clinical recommen-
dations to help the general internist manage this
common clinical problem.
Data sources: Systematic review of the literature
with evaluation of data-related evidence and fram-
ing of graded recommendations.
Data synthesis: Atrial fibrillation affects some
1% of the population in Western countries and is
linked to a significant increase in morbidity and
mortality. The management of atrial fibrillation
requires individualised evaluation of the risks and
benefits of therapeutic modalities, relying when-
ever possible on simple and validated tools. The
two main points requiring a decision in clinical
management are 1) whether or not to implement
thromboembolic prevention therapy, and 2)
whether preference should be given to a “rate con-
trol” or “rhythm control” strategy. Thromboem-
bolic prophylaxis should be prescribed after indi-
vidualised risk assessment: for patients at risk, oral
anticoagulation with warfarin decreases the rate of
embolic complications by 60% and aspirin by
20%, at the expense of an increased incidence of
haemorrhagic complications. “Rate control” and
“rhythm control” strategies are probably equiva-
lent, and the choice should also be made on an in-
dividualised basis. To assist the physician in mak-
ing his choices for the care of an atrial fibrillation
patient we propose specific tables and algorithms,
with graded recommendations. 
Conclusions: On the evidence of data from the
literature we propose simple algorithms and tables
for the clinical management of atrial fibrillation in
the individual patient. 
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We selected important points requiring decision in
the management of AF, such as pathogenesis, epidemiol-
ogy, diagnosis, investigations, cardioversion techniques,
rate and rhythm control, and thromboembolic prophy-
laxis. For each of these aspects we conducted a specific
literature search using the Medline® database with the
MeSH word “atrial fibrillation”, limited to the publication
types “review”, “clinical study”, and “meta-analysis”. We
restricted the search to articles issued after 1980. Articles
specifically addressing the topic of interest were selected
by reading the title and the abstract, with an assessment of
the methodological quality of the data whenever possible.
Case reports or small series were rejected. The extended
versions of all selected papers were then more fully
analysed. The evidence level of data was evaluated by con-
sensus among the authors, based on the usual criteria. For
each topic of interest guidelines were developed and
graded on three levels: level A was based on at least 2 ran-
domised controlled trials with a sufficient sample popula-
tion, or on a meta-analysis with appropriate methodology,
or lastly on basic science evidence. Level B recommenda-
tions were based on non-randomised trials or on trials cov-
ering an inadequate sample population. Experts’ opinions,
retrospective cohort analyses, and case-control studies
resulted in level C recommendations. After internal and
external review the guidelines were implemented in the
Department of Internal Medicine of the Centre Hospital-
ier Universitaire Vaudois in Lausanne. 
This paper presents the main results of this work of
collaboration. In the form of answers to frequently asked
questions, we propose a summary of the guidelines in con-
junction with tables and algorithms. The recommenda-
tions are not intended to replace the physician’s clinical
judgment but rather to assist him in taking management
decisions. 
Guidelines for atrial fibrillation
Methods
Results
Overview of the clinical problems of AF
What is the definition of AF?
AF is a rapid and irregular atrial arrhythmia
with a frequency of over 300 beats per minute,
characterised by irregular or absent auricular
mechanical activity [4]. Diagnosis is based on the
ECG, where normal auricular P waves are replaced
by rapid and irregular oscillations corresponding
to the atrial f (for atrial fibrillation) waves. 
What is the mechanism of AF?
AF results from simultaneous reentrant
wavelets, secondary to increased atrial automatic-
ity and/or excitability, combined with slowing of
conduction and/or shortening of the effective re-
fractory period [4, 5]. Pulmonary veins are an im-
portant source of ectopic beats which may initiate
AF, particularly when intra-atrial pressure is in-
creased [6, 7]. The rapid onset of electrical atrial
remodeling after AF initiation favours the per-
petuation of the arrhythmia [4]. The autonomic
nervous system plays a prominent role in the
occurrence and persistence of the arrhythmia, by
modulating the atrial refractory period [4, 8].
What is the epidemiology of AF? 
In the Western world 5% of the population
will develop AF during their lives [9]. The preva-
lence of AF in the general population is 0.5 to 1%
but increases with age, rising to 10% in persons
over 80 [10, 11]. The annual incidence varies from
0.1% under the age of 55 to more than 3% in the
over-85s [10, 11]. AF is more frequent in men, but
since women live longer they represent the major-
ity of patients aged over 75 [10–12]. Ageing of the
population increases the prevalence of AF and re-
sults in more frequent hospital admission [11, 13]. 
What are the clinical manifestations of AF?
Up to one-third of patients are asymptomatic
[12, 14], but this proportion may be higher since
asymptomatic patients often go undiagnosed.
Most symptomatic patients report palpitations,
dyspnoea, thoracic pain and asthenia, of increased
intensity on physical activity. Clinical signs include
an irregularly irregular pulse, often with a periph-
eral pulse deficit, an absent jugular venous a wave,
and an irregular first heart sound [15].
Is there a simple clinical classification of AF?
Although somewhat arbitrary, clinical classifi-
cations of AF may simplify its clinical management
[3, 16]. A collaborative working group recently
proposed a consensus on nomenclature and classi-
fication of AF, in which initial episodes are distin-
guished from paroxysmal, persistent, or perma-
nent ones [17] (table 1). 
AF can also be classified into idiopathic or
“lone” AF, which represents 40–60% of paroxystic
episodes of AF, and secondary forms, most often
associated with cardiac diseases [12]. Nowadays
rheumatic heart disease is only rarely encountered,
and hypertensive cardiopathy is the first cause of
secondary AF, followed by coronary artery disease,
myopericarditis, cardiomyopathies, non-rheu-
matic valvular disease and cardiac surgery [10, 12,
18]. Hyperthyroidism, alcohol consumption, lung
disease and hypoxaemia, and electrolytic distur-
bances may also trigger AF [15, 19].
What are the clinical consequences of AF? 
Epidemiological studies have shown that AF is
associated with increased morbidity and mortality,
with lowered quality of life, mainly due to stroke
and heart failure [12, 18, 20–24]. 
AF is associated with a 5-fold increase in the
risk of stroke (a 15-fold increase in rheumatic heart
disease) and with an increase in the severity of
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stroke, and is therefore the cause of the majority of
cardioembolic strokes [9, 10, 25–29]. Cognitive
defects may be detected in many patients with AF,
together with asymptomatic embolic events on
brain CT scan [30, 31]. Independent risk factors
for development of stroke are age, hypertension,
diabetes mellitus, previous stroke or transient is-
chaemic attack, heart failure and coronary artery
disease, with a cumulative effect [3, 32, 33].
Decreased ventricular filling time and loss of
atrial contractions may result in decreased cardiac
output and overt cardiac failure in 15–50% of pa-
tients [15, 34]. However, AF and cardiac failure are
so frequently associated that it is impossible to
know which precedes the other. AF occurring in
patients with heart failure and heart failure devel-
oping in AF patients significantly worsen the prog-
nosis [35]. After several weeks of AF, mechanical
remodeling or tachycardia-induced cardiomyo-
pathy may affect the atrial myocardium, but its 
role in the development of heart failure may be of
importance only in long-lasting episodes of AF
[36, 37].
Management of AF: practical guidelines
What investigations should be performed 
at the time of diagnosis? 
ECG must be performed to confirm a clinical
diagnosis and to detect an underlying cardiac dis-
ease (Level A). History and clinical examination
are important for the classification of AF (table 1),
the evaluation of AF tolerance, to detect associated
diseases and to guide investigations (Level C) [37,
38]. Hyperthyroidism screening is necessary only
in the presence of suggestive clinical signs and for
recurrent AF episodes (Level C) [39, 40]. For pa-
tients who are or will be treated with amiodarone,
thyroid function test can be prescribed as part of
the therapy follow-up. Long-term ECG monitor-
ing (Holter or loop-recording) may be useful for
detection of asymptomatic episodes or to confirm
clinical suspicion of intermittent AF (Level C). 
Although not mandatory, transthoracic echocar-
diography (TTE) may confirm clinical suspicion
of heart failure and is a sensitive test for detection
of systolic or diastolic dysfunction or valve disease
(Level C) [38, 41]. 
Should newly discovered AF always be cardioverted? 
In the presence of significant haemodynamic
instability or severe hypoperfusion, urgent electri-
cal cardioversion should be performed (Level C).
In all other situations the timing and mode of car-
dioversion should be evaluated on an individual
basis (table 2 and figure 1). 
When the onset of AF is known and the dura-
tion is less than 48 hours, spontaneous cardiover-
sion is very frequent [42] and cardioversion is usu-
ally recommended only if spontaneous cardiover-
sion does not occur within the first 48 hours after
onset of the arrhythmia (Level C) [43]. Although
embolic complications are extremely rare in this
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episodes cardioversion
number duration spontaneous after treatment
Initial event paroxysmal unique <48 h always always
(acute atrial fibrillation) recent onset unique 48 h to 7 d possible possible
first detected unique unknown rare possible
Chronic atrial fibrillation intermittent (recurrent) relapses <7 d frequent possible
persistent relapses >7 d impossible possible
permanent (accepted) relapses >7 d impossible impossible
Table 1
Clinical classification
of atrial fibrillation
(adapted from Levy
et al. [16, 17]).
treatment Level
Haemodynamic compromise immediate cardioversion C
AF of less than 48 hours’ duration therapeutic anticoagulation (INR 2.0–3.0) C
with stable haemodynamic conditions treat any precipitating cause C
ventricular rate control C
cardioversion before 48 hours’ duration (immediate or delayed) A
therapeutic anticoagulation for 4 weeks after cardioversion B
AF of more than 48 hours or immediate therapeutic anticoagulation (INR 2.0–3.0) C
of unknown duration with evaluate risks and benefit of cardioversion C
stable haemodynamic conditions
discuss TEE: if possible, check for contra-indication to cardioversion, B
and if no, immediate cardioversion
anticoagulation for 3 weeks before cardioversion (INR 2.0–3.0) A
with ventricular rate control
anticoagulation for 4 weeks after cardioversion (INR 2.0–3.0) B
INR: international normalized ratio
TEE: transoesophageal echocardiography
Table 2
Guidelines for
cardioversion of
atrial fibrillation.
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Figure 1 
Management of an
initial acute episode
of AF. MAP: mean
arterial pressure;
TEE: transoeso-
phageal echo-
cardiography.
Acute atrial fibrillation (initial diagnosis)
hemodynamic instability?
map <70 mm Hg
or 
vital organ hypoperfusion
no yes
“rhythm control”
option
“rate control”
option
see fig. 3
immediate electrical
cardioversion
<48 hours duration? sinus rhythm?
yes no/unknown
precipitating factor?
TEE at hand and showing
no contraindications to
immediate cardioversion?
no yes
yes no
treat
oral
anticoagulation
+ 
rate contol
no yes
no yes
assess risk/benefit
of oral
anticoagulation
4 weeks
oral
anticoagulation
3 weeks
+ 
rate contol
oral anticoagulation
≥4 weeks
cardioversion
fluids and vasopressors
+
oral anticoagulation
3 weeks vs TEE-guided
+
rhythm control
+
treat precipitating factor
oral
anticoagulation
4 weeks
+ 
rhythm contol
AF still present
at 48 hours?
situation [44], most experts recommend immedi-
ate therapeutic anticoagulation for 3 weeks after
cardioversion (Level C) [45, 46]. 
In all other situations (unknown onset, persis-
tent and intermittent AF), or unknown onset (re-
cent onset or recent diagnosis), cardioversion
should be built into a global strategy: the “rhythm
control” option, which includes cardioversion and
maintenance of sinus rhythm, and the “rate
control” option, without cardioversion but with
control of ventricular rate (figure 3). Randomised
controlled trials have compared these two strate-
gies (PIAF, AFFIRM, RACE and STAF) and
shown that they do not influence quality of life and
mortality and can be considered equivalent for
most patients (Level A) [47–50]. The choice be-
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Elective cardioversion of atrial fibrillation
depending on:
technique availability
patient’s preference
physician’s preference
electrical cardioversion pharmacological cardioversion
sinus rhythm?
yes no
oral anticoagulation
≥4 weeks
±
rhythm control
use other technique
yes sinus rhythm?
no
can chronic AF be tolerated by the patient?
(depending on ventricular function, symptoms,
contraindications to long-term oral anticoagulation)
no yes
refer to AF specialist rate control
+
oral anticoagulation
Figure 2
Elective cardio-
version of AF.
tween “rate control” and “rhythm control” should
therefore be made after thorough individual eval-
uation of the risk and benefit of both strategies.
The physician should therefore assess subjective
tolerance and symptoms associated with the ar-
rhythmia, the presence of heart failure or other
cardiovascular diseases, the patient’s preference
and compliance with therapy, and the risk/benefit
ratio of drug therapies before any choice is made.
The relatively low success rate of “rhythm control”
should also be considered.
What is the preferred cardioversion technique? 
The choice between electrical and pharmaco-
logical cardioversion is mainly influenced by their
availability and the physician’s and patient’s pref-
erence (figure 2). Both techniques require a short
hospital stay for temporary rhythm monitoring
[51], and are burdened with potential complica-
tions, associated with sedation and analgesia for
electrical cardioversion, and with rhythmic and
hypotensive complications for pharmacological
cardioversion [52]. The combination of both
techniques, starting with drug administration, fol-
lowed in the event of failure by electrical car-
dioversion, could be an interesting and cost-effec-
tive way of increasing the success rate [53–56].
The success rate of cardioversion essentially de-
pends on the duration of the arrhythmia and the
patient’s age; the longer the duration and the older
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the patient, the lower the rate of cardioversion 
[57, 58]. 
Electrical cardioversion is the most widespread
and probably the most effective mode of restoring
sinus rhythm [37, 43, 51, 59]. Biphasic mode is about
to replace the standard monophasic mode since it is
equally effective but requires lower energy levels
[60–63]. Anterior-posterior positioning of the elec-
trode for DC cardioversion appears to be more ef-
fective than anterior-lateral positioning [64]. 
Many factors influence the effectiveness of
pharmacological cardioversion, such as the dura-
tion of AF or the presence of cardiac or valvular
diseases: the highest conversion rates are reported
for AF of short duration in otherwise ‘healthy’ pa-
tients. Drug comparisons are flawed by the inade-
quate methodology of trials [65]. Nonetheless,
Vaughan-Williams class Ic and III drugs, such as
flecainide, propafenone, ibutilide, dofetilide and
amiodarone, are usually considered effective drugs
[37, 65–68] (table 3). A recent meta-analysis
showed that amiodarone was as effective as IC
drugs for cardioversion in acute AF at 24 hours, al-
though cardioversion was slower (Level A) [68]. All
Guidelines for atrial fibrillation
Chronic atrial fibrillation
is cardioversion
useful and possible?
yes cardioversion
no
embolic complications
prevention
individualized strategy
rhythm control
precipitating factor
for AF?
rate control
left ventricular
dysfunction
yes no yes no
treat
digoxin
or
beta-blocker
risk stratification: CHADS2
Cardiac failure: 1 pt
Hypertension: 1 pt
Age >75 yrs 1 pt
Diabetes: 1 pt
Stroke / TIA: 2 pts
CHADS2 >3 pts
no yes
individualized
rhythm control
beta-blocker
or
calcium channel
blocker
rate control satisfying?
no yes
associate
beta-blockers
with
calcium chanel
blockers
continue
therapy
CHADS2 >1 pt
no yes
contra-indication to
oral anticoagulation?
yes no
no therapy AAS 300 mg/d
oral
anticoagulation
INR 2.0–3.0
Figure 3
Management 
of chronic AF
AAS: aspirin
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other drugs are either ineffective or of unproven
efficacy, and should therefore not be used as first-
line treatment.
How should anticoagulation be prescribed 
before and after cardioversion? 
Therapeutic anticoagulation with intravenous
unfractioned heparin (UFH) should always be pre-
scribed at the time of AF diagnosis and its effec-
tiveness assessed, for example with the aPTT or an
ACT. Low molecular weight heparins are as effec-
tive, easier to use, and could shorten the hospital
stay (Level B) [69, 70]. Heparin anticoagulation
must be rapidly replaced by oral anticoagulation
with warfarin or derivatives, within 3–5 days. The
duration of treatment thereafter depends on the
therapeutic strategy (table 2).
If cardioversion is the preferred option, it
should be performed only after a three-week pe-
riod of controlled anticoagulation (INR 2.0–3.0,
with twice weekly monitoring), the only exception
being AF of less than 48 hours’ duration. During
this period the INR should not fall below 2.0, oth-
erwise a new 3-week period of oral anticoagulation
should be started. This could explain a longer than
recommended duration of anticoagulation in real-
life medical practice [71]. The ACUTE study has
shown that immediate cardioversion can be safely
performed in the absence of auricular thrombi 
or spontaneous auricular contrast in transoeso-
phageal echocardiography (TEE) (Level B), thus
reducing the rate of haemorrhagic complications
[72, 73]. However, post-cardioversion anticoagu-
lation is still mandatory, though the absence of a
cost-effectiveness analysis and the restricted avail-
ability of TEE in clinical practice limit its wide-
spread use. 
Transient atrial mechanical dysfunction is fre-
quent after cardioversion and usually lasts only a
few hours, in rare cases over a week [74–76]. After
4 weeks of sinus rhythm, atrial mechanical func-
tion should be normalised in most patients [77].
Effective anticoagulation must therefore be main-
tained for at least 4 weeks after cardioversion
(Level B). The intensity of anticoagulation should
be regularly monitored (INR 2.0–3.0).
How should the risk of embolic complications 
of AF be evaluated? 
Risk stratification for the development of
stroke can be based on clinical factors [33, 78].
Many stratification systems have been validated
which combine similar items such as age, hyper-
tension, cardiac failure, history of stroke or dia-
betes [3, 33, 79–84]. The CHADS2 (Cardiac fail-
ure, Hypertension, Age >70, Diabetes, history of
Stroke or transient ischemic attack) score (table 4)
is easy to use [33]. The recently published Fram-
ingham score is more complicated but may be use-
ful in case of doubt [84]. A minority of patients are
at increased risk of thromboembolic complications
in the absence of clinical risk factors, but system-
atic use of TEE for risk assessment is not recom-
mended (Level B) [83]. 
How should embolic complications of AF be prevented? 
Oral anticoagulation (INR of 2.0–3.0) is rec-
ommended for all chronic forms of AF (persistent,
permanent, and recurrent) in the presence of a sig-
nificant risk of stroke and in AF associated with
rheumatic valvular diseases (INR 3.0–4.0) [25, 26,
46]. It can be very difficult to prove the mainte-
nance of sinus rhythm even with continuous am-
bulatory ECG monitoring, and anticoagulation
should therefore be prescribed indefinitely for the
majority of patients (Level C). This is particularly
true of recurrent asymptomatic AF episodes,
which are very difficult to detect but are associated
with a similar risk of stroke to permanent or per-
sistent AF [14, 27, 49]. Moreover, AF relapses are
very frequent and often asymptomatic in patients
treated with anti-arrhythmic drugs [49].
Eleven randomised trials of primary (I) or
secondary (II) prevention [78] (SPAF 1, 2, and 3 (I)
[81, 85–87], CAFA (I) [88], SPINAF (I/II) [89],
AFASAK 1 and 2 (I) [90, 91], BAATAF (I) [92],
EAFT (II) [93], and PATAF (I) [94]) have shown,
despite methodological drawbacks, the benefit 
of antithrombotic prevention [78, 95–98], with a
60% reduction (47 to 71%, 95% confidence inter-
val) in the relative risk of stroke associated with an-
ticoagulation compared to placebo. This compares
favourably with the 20% (4–36%) reduction ob-
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Drug class dose range contraindications conversion rate time to conversion
Propafenone Ic oral: 150–600 mg ventricular dysfunction 40–75% 3–8 hours
one dose severe asthma
Flecainide Ic oral: 100–400 mg ventricular dysfunction 70–90% 1–8 hours
one dose active ischaemia
diuretic therapy
Amiodarone III intravenous:  bradycardia 40–90% 1–24 hours
150–300 mg in 20 min less effective in 
oral: 30 mg/kg acute AF
or
0.8–1.6 g/d (total 10 g)
Ibutilide III intravenous: 0.1 mg/kg left ventricular 30–70% 1 hour
in 10 min dysfunction
repeat after 10 minutes prolonged Q-T interval
if no response
Class: Vaughan-Williams classification
Table 3
Drugs for AF cardio-
version.
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tained with aspirin, and anticoagulation reduces
the risk of stroke by 33% (16–50%) compared with
aspirin, with an increase in the risk of hemorrhage
[97]. Several recent “outcome studies” have con-
firmed these results over longer periods of time in
unselected outpatients [99–102].
What risk is involved in anticoagulation for AF? 
Even though the proportion of treated pa-
tients has quadrupled since 1990, oral anticoagu-
lation is still underprescribed in AF, mainly be-
cause of fear of haemorrhagic complications
[103–108]. To limit this risk an INR between 2.0
and 3.0 is recommended, with close monitoring
[109, 110]. Recently published data suggest that
the rate of complications is not increased in cases
with previous episodes of upper gastrointestinal
tract bleeding, predisposition to falling and old
age, and there is only conflicting evidence that
alcoholism, the presence of a bleeding diathesis 
or non-compliance with monitoring increase this
risk [108]. Fear of haemorrhagic complications 
is therefore often greater than the real risk. The
haemorrhagic risk should nevertheless be assessed,
but there are no validated tools for such evaluation
in patients with AF. For the vast majority of pa-
tients with AF the benefit of thromboembolic pro-
phylaxis largely outweighs the risk of hemorrhagic
complications [108, 111]. The Landefeld-Beyth
score is based on 4 independent factors (age >65
years, history of stroke, of gastro-intestinal bleed-
ing and of serious co-morbidity such as myocardial
infarction or renal failure), but has only been vali-
dated for patients with venous thromboembolic
diseases [112–114]. Its usefulness for patients with
AF is less evident, since most AF patients with a
clear indication for anticoagulant prophylaxis are
also at high risk of bleeding complications, as pre-
dicted by this score. Close monitoring of the level
of anticoagulation is therefore the key to safe pre-
scription in most patients, e.g. the very elderly
(Level C) [115]. The patient can participate in the
decision to introduce thromboembolic prevention
therapy, thus improving his quality of life and re-
ducing costs compared with systematic prescrip-
tion (Level B) [116, 117].
How can “rhythm control” be obtained? 
One year after cardioversion more than two
thirds of patients present a recurrence of AF [37,
49, 50, 118]. The main risk factors for recurrence
are functional NYHA class before cardioversion
and non-rheumatic origin of AF [119]. Clinical tri-
als have shown that most drugs are more efficient
than placebo in maintaining sinus rhythm, but
with such poor methodology that recommenda-
tions are difficult to formulate [37, 65]. The indi-
vidual risks and benefits of each therapeutic agent
must be evaluated, and co-morbidities should
guide the choice of drug. 
With amiodarone (100 to 200 mg/d) sinus
rhythm is maintained after one year in more than
50% of patients [37, 49, 120, 121]. Its side effects
are generally tolerable, except for the rare hyper-
thyroidism and lung toxicity. Its proarrhythmo-
genic effect is low, but high-degree heart block is
frequent in older patients, particularly women
[122]. Dofetilide is a promising drug, particularly
for heart failure patients [123]. Sotalol is less effec-
tive than amiodarone in this situation [120, 121].
Class I drugs (flecainide, quinidine, disopyramide
and propafenone) are effective but their side effects
may outweigh their antiarrhythmic properties,
particularly in patients with structural heart dis-
ease [121, 124, 125]. 
How can “rate control” be obtained? 
In acute episodes of AF, rate control (90–100
per minute) should be rapidly obtained, intra-
venous administration being the route of choice
(table 5). Calcium channel blockers and beta-
blockers are more rapidly effective than digoxin,
and combination is sometimes necessary [126–
129]. Intravenous administration of calcium chan-
nel blockers and beta-blockers may be associated
with significant hypotension, and patients should
therefore be closely monitored during the pro-
cedure.
In chronic forms of AF pharmacological con-
trol of ventricular rate is the first choice (table 5),
and interventional therapies should be considered
only after treatment failure [130]. A ventricular
rate of 90–100 per minute is generally recom-
mended, but must be individualised on the basis of
Guidelines for atrial fibrillation
Cardiac failure 1 point
Hypertension 1 point
Age over 75 years 1 point
Diabetes mellitus 1 point
History of stroke or transient ischaemic attack 2 points
Risk of stroke Prevention of thromboembolic Level
(per 100/yr) complications
CHADS2 >3 8.5 to 18.2% Oral anticoagulation (INR 2.0–3.0) A
CHADS2 2–3 4.0 to 5.9% Oral anticoagulation (INR 2.0–3.0) A
or aspirin (300 mg/d)
CHADS2 0–1 1.9 to 2.8 % <55 years old: nil A
>55 years old: aspirin (300 mg/d)
Table 4
Stratification and
prevention of throm-
boembolic risk with
the CHADS2 score.
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symptoms and signs, particularly during exercise
[131, 132]. Digoxin is more effective than placebo,
but rate control is rarely satisfactory during exer-
cise and should therefore be prescribed only to
patients with concomitant systolic dysfunction
[130, 131, 133, 134]. Beta-blockers are very effec-
tive alone or in combination [134, 135]; their side
effects, such as symptomatic bradycardia and heart
blocks, are rare, though more frequent in elderly
patients [131]. The beneficial effect of beta-block-
ers in patients with chronic heart failure makes
them an alternative to digoxin [136–138]. Non-
dihydropyridine calcium channel blockers, such as
diltiazem and verapamil, are more effective than
digoxin [130, 134, 135]. A significant fall in blood
pressure is frequent but well tolerated in most pa-
tients [127], and heart blocks only rarely occur in
older patients or in association with beta-blockers
or digoxin [134]. Amiodarone for rate control
should be restricted to first-line drug failure or
contraindications [134]. 
What is the place of interventional therapies? 
Such therapies were initially proposed years
ago, but never imposed themselves as relevant
therapeutic options. Many new procedures have
recently been further developed, and a large body
of data now shows that in the near future interven-
tional therapies may become a satisfactory option
for the management of many patients with AF.
However, due to their recent development and
their relatively limited availability they nowadays
only apply to complex situations in which “stan-
dard” treatments have failed. These therapies can
be divided into palliative, preventive and curative
strategies. Palliative approaches, such as complete
or selective ablation of the atrioventricular con-
duction pathways, associated with definitive ven-
tricular pacing, are indicated when the ventricular
rate is not under control despite optimal medical
therapy [139]. Preventive techniques, centred on
surgical or catheter-based modifications of intra-
atrial conduction, have the potential to prevent re-
currence of AF and maintain sinus rhythm in more
than 80% of patients at 6 months [140]. Curative
techniques, such as selective catheter ablation 
of auricular or para-auricular ectopic foci [141], 
or pulmonary vein isolation [142], may cure the
arrhythmia in more than 70% of paroxystic AF. 
In a recent controlled non-randomised trial, pul-
monary vein isolation was associated with an de-
crease in mortality and morbidity compared with
anti-arrhythmic therapy [143]. However, the data
are preliminary and this technology is still limited
to a few centres whose clinical research will assess
its indications and long term complications [144].
An implantable atrial cardioverter is a potentially
interesting device, but its development is ham-
pered by most patients’ poor tolerance of painful
shock deliveries [145]. Finally, the role of various
pacing techniques in the management of AF is
currently under evaluation in several trials [146]. 
Conclusions
AF is an increasingly frequent cardiac arrhyth-
mia. Thanks to progress in therapies and extensive
clinical research, its management can nowadays be
tailored to the patient’s individual characteristics
and the patient’s and physician’s preferences. De-
cision algorithms and recommendation tables can
assist the physician in his decision-making, partic-
ularly in diagnostic and therapeutic areas such as
global strategy, choice of cardioversion mode or
thromboembolism prevention treatment. In all
complex cases, such as treatment failure or unusual
presentations, the patient should be referred to an
AF specialist. 
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Drug class acute AF dosing chronic AF dosing
Diltiazem IV 0.25 mg/kg intravenous bolus in 2 min 180–270 mg/d orally
followed by
5–15 mg/h
under blood pressure monitoring 
Verapamil IV 5–10 mg intravenous dose in 3 min 120–480 mg/d orally
followed by
0.1–0.5 mg/kg/min 
under blood pressure monitoring 
Esmolol II 0.5 mg/kg intravenous bolus in 1 min –
followed by
50–100 mg/kg/min
Metoprolol II 5 mg intravenous bolus in 1 min 25–200 mg/d orally
repeat up to 3 times if necessary
Propranolol II 0.15 mg/kg intravenous bolus in 20 min 10–100 mg/d orally
followed by 
3 mg/h
Digoxin - 0.5 mg intravenous bolus 0.125–0.250 mg/d orally
followed by
0.25 mg after 6 and 12 h
AF: atrial fibrillation
min: minutes
h: hours
Table 5
Drugs for ventricular
rate control.
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